Christopher J. Sweeney, MBBS, presented “Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)” for the Grand Rounds in Urology audience in December 2019.

How to cite: Sweeney, Christopher J. “Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)” December, 2019. Accessed Jan 2020. https://grandroundsinurology.com/update-on-the-arches-trial-new-indication-for-enzalutamide-in-metastatic-hormone-sensitive-prostate-cancer-mhspc/

Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) – Summary:

Investigator Christopher J. Sweeney, MBBS, a medical oncologist at the Dana-Farber Cancer Institute and professor of medicine at Harvard, gives an overview of the trial (a companion to the ARCHES study), which demonstrated a survival benefit in all versions of mHSPC (metastatic hormone-sensitive prostate cancer) with the use of enzalutamide. Dr. Sweeney discusses how ENZAMET builds on the research conducted with ARCHES, the differences between enzalutamide and chemotherapy for high-burden, rapidly progressing disease, and why monotherapy should be phased out for PCa treatment in most patients.